A Bivalent Omicron-Containing Booster Vaccine against Covid-19

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · cited 1×

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., et al. (2022) · Nature · doi:10.1038/s41586-022-04980-y · Cited by 1,306

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Gilbert, P. B., Montefiori, D. C., McDermott, A. B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., et al. (2022) · Science · doi:10.1126/science.abm3425 · Cited by 1,137

Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa

Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., Campbell, T. B., Clark, J., Jackson, L. A., Fichtenbaum, C. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113017 · Cited by 641

Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants

Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., et al. (2022) · doi:10.1101/2022.01.07.22268919 · Cited by 541

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O'Dell, S. J., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119912 · Cited by 447

Structural Exposition of Concern and Belief of COVID-19 Vaccination Knowledge in Ghana

Balogun, O. S., Olaleye, S. A., Mensah, F. A., Agjei, R. O., & Akingbade, T. J. (2023) · Advances in healthcare information systems and administration book series · doi:10.4018/978-1-6684-8103-5.ch008 · Cited by 1

Risk factors for COVID-19 infection in people with 4th dose of bivalent mRNA vaccines in general medicine from October 2022 to February 2023

Turabián, J. L. (2023) · Archives of Community Medicine and Public Health · doi:10.17352/2455-5479.000198 · Cited by 1

Which Factors Were Related to the Number of COVID-19 Cases in the 2022/2023 Season Compared to the 2021/2022 Season in Europe?

Sobczak, M., & Pawliczak, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134517 · Cited by 1

Of Stances, Themes, and Anomalies in COVID-19 Mask-Wearing Tweets

Low, J. F., Fung, B. C. M., & Iqbal, F. (2023) · IEEE Access · doi:10.1109/access.2023.3298557 · Cited by 2

Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open‐label, and single‐arm Phase 1 study

Hannawi, S., Zhang, R., Abuquta, A., Eldin, L. S., Hassan, A., Alamadi, A., Hossain, T., Mostafa, M., Ghoneim, Y., Solo, J., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1387 · Cited by 1

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant

Ávila‐Nieto, C., Vergara‐Alert, J., Amengual-Rigo, P., Ainsua‐Enrich, E., Brustolin, M., de la Concepción, M. L. R., Pedreño-López, N., Rodon, J., Urrea, V., Pradenas, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291972 · Cited by 1

The key to practical application of mRNA technology: A brief analysis of the 2023 Nobel Prize in Physiology or Medicine

Du, P., & Wang, Q. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-1201 · Cited by 1

Effectiveness of Bivalent mRNA Booster Vaccine Against COVID-19 in Korea

Yoon, J. G., Sohn, J. W., Choi, W. S., Wie, S., Lee, J., Lee, J. S., Jeong, H. W., Eom, J. S., Seong, H., Nham, E., et al. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2024.39.e15 · Cited by 1

Advancements in the development of mRNA vaccine against monkeypox virus

Liu, X., Hu, B., Fan, Y., Weng, Y., Huang, Y., & Yang, M. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-1092 · Cited by 1

Effectiveness of the severe acute respiratory syndrome coronavirus 2 Omicron BA.5 bivalent vaccine on symptoms in healthcare workers with BA.5 infection

Hirotsu, Y., Takatori, M., Mochizuki, H., & Omata, M. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100433 · Cited by 1

Intranasal and Inhaled Vaccines

Chow, M. Y. T., & Lam, J. K. W. (2023) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-47567-2_6 · Cited by 1

Modeling the SARS-CoV-2 sublineages XBB and BQ.1 in Mexico, considering multiple vaccinations, booster dose, waning immunity and cross-immunity

de León, U. A.-P., Pérez, Á. G. C., & Avila-Vales, E. J. (2024) · Electronic Research Archive · doi:10.3934/era.2024053 · Cited by 1

Analysis of related factors for RA flares after SARS-CoV-2 infection: a retrospective study from patient survey

Li, R., Zhao, J.-K., Li, Q., Zhao, L., Su, Y., Zhang, J., & Zhang, L.-Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-52748-3 · Cited by 1

Effectiveness of 4th doses of bivalent mRNA vaccine in reinfections from October 2022 to October 2023 in a general medicine office in Toledo (Spain)

Turabián, J. L. (2024) · Archives of Community Medicine and Public Health · doi:10.17352/2455-5479.000207 · Cited by 1

Reinfections of COVID-19 with and Without Fourth Dose of Bivalent mRNA Vaccine in the Period from October 2022 to October 2023 in a General Medicine Office in Toledo (Spain)

Turabián, J. L. (2024) · Journal of Diseases Disorders & Treatments · doi:10.47363/jddt/2024(4)125

Universal characterization of epitope immunodominance from a multiscale model of clonal competition in germinal centers

Ferretti, F., & Mehran Kardar, A. (2024) · Physical review. E · doi:10.1103/physreve.109.064409 · Cited by 2

Progress on the poxvirus vaccine

Zhao, M., Zhang, M., Qin, L., Gao, H., & Zhang, K. (2024) · Veterinary Vaccine · doi:10.1016/j.vetvac.2024.100092 · Cited by 1

Comparative Analysis of the Neutralizing Capacity of Monovalent and Bivalent Formulations of Betuvax-CoV-2, a Subunit Recombinant COVID-19 Vaccine, Against Various Strains of SARS-CoV-2

Vakhrusheva, A., Romanovskaya-Romanko, E., Stukova, M., Sukhova, M. M., Kuznetsova, K. S., Kudriavtsev, A. V., Frolova, M. E., Ivanishin, T. V., Krasilnikov, I. V., & Isaev, A. A. (2024) · Vaccines · doi:10.3390/vaccines12101200 · Cited by 1

Immunogenicity of second booster-dose COVID-19 mRNA vaccine among older adults in Taiwan

Lee, H.-Y., Chuang, C.-H., Huang, C., Chuang, T.-C., Kung, Y.-A., & Chiu, C. (2025) · Biomedical Journal · doi:10.1016/j.bj.2025.100834 · Cited by 2

Comparison of adverse reactions to COVID-19 XBB.1.5 and influenza vaccination in the 2023-24 Japanese influenza season

Kawai, N., Ikematsu, H., Bando, T., Lee, W. J., Matsuura, S., Maeda, T., Echizen, M., & Kawashima, T. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102728 · Cited by 1

Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history

Wang, R., Lyu, Y., Chen, M., Sun, L., Zhou, S., Cui, Y., Ma, J., Kong, D., Lu, J., Li, X., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02907-24 · Cited by 1

Beyond immunogenicity: durability, dosing, and target populations for XBB.1.5 subunit COVID-19 boosters

Norkaew, J., Gordon, C. N., Rattanapitoon, S. K., & Rattanapitoon, N. K. (2025) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2025.100674 · Cited by 1

SARS-CoV-2-specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressiva patients

Smetanová, J., Milota, T., Rataj, M., Hurňáková, J., Zelená, H., & Horváth, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017232 · Cited by 1

From Monitoring the Commitment to Inoculations among Healthcare Workers during the COVID-19 Pandemic to Overcoming Communication Risks in the Process of Vaccination

Platonova, T. A., Golubkova, A. A., Sklyar, M. S., Sisin, E. I., Смирнова, С. С., Tomenko, T. R., & Rozhkov, M. S. (2023) · ЗДОРОВЬЕ НАСЕЛЕНИЯ И СРЕДА ОБИТАНИЯ - ЗНиСО / PUBLIC HEALTH AND LIFE ENVIRONMENT · doi:10.35627/2219-5238/2023-31-1-13-19

Retrospective View of COVID-19 Pandemic: Treatment, Management and Development of Preventive Measures

Tym, P., Bayey, E., Brittain, A., Huang, A., Nandagopal, V., Singh, A., Scarlett, C., & CY, C. B. W. (2023) · Reports on Global Health Research · doi:10.29011/2690-9480.100158

Risk Factors for Re-Infection of Covid-19 with Fourth Dose versus without Fourth Dose of Bivalent mRNACovid-19 Vaccines

(2023) · Archives of Health Science · doi:10.31829/2641-7456/ahs2023-7(1)-017

La química española en el siglo XIX

Sáiz, A. S., & Marco, E. P. (1992) · Ayer · Cited by 1

UB-612 Multitope Vaccine Targeting SARS-CoV-2 Spike and Non-Spike Proteins Provides Broad and Durable Immune ResponsesPreprint

Wang, C. Y., Peng, W., Kuo, B.-S., Liu, H., Ho, Y.-H., Wang, M.-S., Yang, Y.-T., Chang, P.-Y., Shen, Y.-H., & Hwang, K. (2022) · medRxiv · doi:10.1101/2022.08.26.22279232 · Cited by 1

A Beta-containing bivalent SARS-CoV-2 spike protein vaccine candidate with AS03 elicits durable and broad neutralization of variants including Omicron in macaques and confers protection in hamstersPreprint

Berry, C., Pavot, V., Anosova, N. G., Kishko, M., Huang, D., Tibbitts, T., Raillard, A., Gautheron, S., Cummings, S., Bangari, D. S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1928234/v1 · Cited by 1

Long-term humoral response following simultaneous Delta and Omicron BA.1 co-infectionPreprint

Saade, C., Pozzetto, B., Yaugel-Novoa, M., Lina, B., Paul, S., Bal, A., & Trouillet‐Assant, S. (2022) · medRxiv · doi:10.1101/2022.10.28.22281636 · Cited by 1

Robust generation of neutralising antibodies against Omicron variants following bivalent mRNA booster vaccine in elderly people aged >80 years

Parry, H., Bruton, R. K., Uwenedi, G., Roberts, T., Sylla, P., Cook, J. A., Elzaidi, A., Lau, M., Drury, T., Bray, A., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.08.014 · Cited by 1

Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations by a Multivariant Surrogate Virus Neutralization MicroarrayPreprint

Springer, D. N., Höltl, E., Prüger, K., Puchhammer‐Stöckl, E., Aberle, J. H., Stiasny, K., & Weseslindtner, L. (2023) · Preprints.org · doi:10.20944/preprints202311.1035.v1 · Cited by 1

Bivalent COVID-19 vaccines boost the capacity of pre-existing SARS-CoV-2-specific memory B cells to cross-recognize Omicron subvariantsPreprint

Fryer, H. A., Geers, D., Gommers, L., Zaeck, L. M., Tan, N. H., Jones, B., Goorhuis, A., Postma, D. F., Visser, L. G., Hogarth, P. M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.20.585861 · Cited by 1

Design and Development of mRNA Vaccines to Combat the COVID ‐19 Pandemic

Tombácz, I. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch8 · Cited by 1

Exploring Temporal and Spatial Characteristics of Serious Adverse Event Reports Following COVID-19 Bivalent VaccinesPreprint

Li, Y., Tao, W., Dang, Y., Chen, Y., & Tao, C. (2025) · Research Square · doi:10.21203/rs.3.rs-6096098/v1 · Cited by 1

Bivalent mRNA booster encoding virus-like particles elicits potent polyclass receptor-binding domain antibodies in pre-vaccinated micePreprint

Fan, C., Cohen, A. A., Dam, K.-M. A., Rorick, A. V., Fils, A.-C. I. P., Yang, Z., Gnanapragasam, P. N. P., Segovia, L. N., Huey‐Tubman, K. E., Moon, W. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.18.670983 · Cited by 1

Bivalent mRNA booster encoding virus-like particles elicits potent polyclass receptor-binding domain antibodies in pre-vaccinated micePreprint

Fan, C., Cohen, A. A., Dam, K.-M. A., Rorick, A. V., Fils, A.-C. I. P., Yang, Z., Gnanapragasam, P. N. P., Segovia, L. N., Huey‐Tubman, K. E., Moon, W. J., et al. (2025) · eLife · doi:10.7554/elife.108959 · Cited by 1

Vieux bois en haute-savoie, savoie, Italie, Suisse, France pour construction et aménagement, chalet, carnotze, mazot et maison individuelle.

Chardon, N. (2013)

Impfung gegen coronavirus disease 2019 (COVID-19)

Weinberger, B. (2022) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-022-02102-x

Neutralization of SARS-CoV-2 Omicron BA.4/BA.5 subvariant by a booster dose of bivalent adjuvanted subunit vaccine containing Omicron BA.4/BA.5 and BA.1 subvariantsPreprint

Kuo, T., Lien, C.-E., Lin, Y., Lin, M., Liu, L. T.-C., Wu, C.-C., Tang, W.-H., & Chen, C. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.07.511263

Outpatient management of adults with COVID-19

Pullen, R. L. (2022) · Nursing · doi:10.1097/01.nurse.0000884768.80493.fb

Vaccine- and BTI-elicited pre-Omicron immunity more effectively neutralizes Omicron sublineages BA.1, BA.2, BA.4 and BA.5 than pre-Omicron infection alonePreprint

da Silva, E. S., Servais, J.-Y., Kohnen, M., Arendt, V., Gilson, G., Staub, T., Seguin‐Devaux, C., & Perez-Bercoff, D. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.24.513415

Covid-19 : quelle prise en charge pour l’automne 2022 ?

Chollet, V., Manuel, O., & Vallière, S. D. (2022) · JMIG · doi:10.53738/revmed.2022.18.802.2077

Enhanced stability of the SARS CoV-2 spike glycoprotein trimer following modification of an alanine cavity in the protein corePreprint

Poumbourios, P., Langer, C., Boo, I., Zakir, T., Akerman, A., Milogiannakis, V., Aggarwal, A., Turville, S. G., & Drummer, H. E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.08.515567

Winter is coming

Weninger, W. (2022) · hautnah · doi:10.1007/s12326-022-00551-0

Protection against infection with the Omicron BA.5 subvariant among people with previous SARS-CoV-2 infection - surveillance results from southern Sweden, June to August 2022Preprint

Kahn, F., Bonander, C., Moghaddassi, M., Bennet, L., Malmqvist, U. P., Inghammar, M., & Björk, J. (2022) · medRxiv · doi:10.1101/2022.11.08.22282069

The Need to Vaccinate Against COVID-19

Sim, T. C. (2022) · Journal of Medicine University of Santo Tomas · doi:10.35460/2546-1621.2022-0058

Infection and vaccine induced Spike antibody responses against SARS-CoV-2 Variants of concern in immune naïve children and adultsPreprint

Pillay, A., Yeola, A., Tea, F., Denkova, M., Houston, S., Burrell, R., Merheb, V., Lee, F. X. Z., Moran, L., Jadhav, A. D., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2262275/v1

Prevalence and clinical outcome of Omicron breakthrough infection in patients with hematologic disease: a prospective observational cohort studyPreprint

Narita, K., Ikeda, D., Seki, M., Fukumoto, A., Tabata, R., Uesugi, Y., Miura, D., Takeuchi, M., Doi, M., Umezawa, Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2353891/v1

Axillary lymphadenopathy following bivalent COVID-19 booster vaccination

Lane, E. G., Babagbemi, K., Mema, E., & Dodelzon, K. (2022) · Clinical Imaging · doi:10.1016/j.clinimag.2022.12.003

Enhanced Protection from SARS-CoV-2 Variants by MVA-Based Vaccines Expressing Matched or Mismatched S Proteins Administered Intranasally to hACE2 MicePreprint

Cotter, C. A., Americo, J. L., Earl, P. L., & Moss, B. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.03.518963

Is it possible to flatten-the-curve after the initial outbreak of Covid-19? A data-driven modeling analysis for Omicron pandemic in ChinaPreprint

Sun, J., Li, Y., Shao, N., & Liu, M. (2022) · medRxiv · doi:10.1101/2022.12.21.22283786

Fully Quantitative Measurements of Differential Antibody Binding to a Spectrum of SARS-CoV-2 Spike Proteins: Wuhan, Alpha, Beta, Gamma, Delta, Omicron BA.1, BA.4, BA.5, BA.2.75 and BA.2.12.1Preprint

James‐Pemberton, P. H., Kohli, S., Westlake, A. C., Antill, A., Hunt, J., Olkhov, R. V., & Shaw, A. M. (2023) · medRxiv · doi:10.1101/2023.01.11.23284431

Is it possible to flatten-the-curve after the initial outbreak of Covid-19? A data-driven modeling analysis for Omicron pandemic in ChinaPreprint

Liu, M., Sun, J., Yusi, L. I., & Shao, N. (2023) · Research Square · doi:10.21203/rs.3.rs-2404162/v1

A booster dose of either BNT162b2 or mRNA-1273 mRNA vaccines induces a robust recall of anti-SARS-CoV-2 spike protein IgG antibodies in salivaPreprint

Turner, F. E., Brown, R., Chellamuthu, P., Saavedra, E., Denny, N., Santacruz, M., Angel, A. N., MacMullan, M. A., Shacreaw, M., Lopez, L., et al. (2023) · doi:10.22541/au.167784336.67563988/v1

Long-term impacts of SARS-CoV-2 on gastrointestinal tractPreprint

He, K.-Y., Lu, L., Xu, Z., & Jian, Y. (2023) · doi:10.33774/coe-2023-s7pnp

Humoral and cellular response three months following bivalent booster administrationPreprint

Favresse, J., Gillot, C., Bayart, J., Closset, M., Wauthier, L., Cabo, J., David, C., Elsen, M., Dogné, J., & Douxfils, J. (2023) · Research Square · doi:10.21203/rs.3.rs-2715620/v1

Safety, Tolerability, and Immunogenicity of COVID-19 Bivalent Vaccination

Saxena, D., Batra, L., & Verma, S. K. (2023) · Vaccines · doi:10.3390/vaccines11061040

Prevalence and Clinical Outcome of Omicron Breakthrough Infection in Patients With Hematologic Disease: A Prospective Observational Cohort Study

Narita, K., Ikeda, D., Seki, M., Fukumoto, A., Tabata, R., Uesugi, Y., Miura, D., Takeuchi, M., Doi, M., Umezawa, Y., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000905

Potent induction of humoral and cellular immunity after bivalent BA.4/5 mRNA vaccination in dialysis patients with and without history of SARS-CoV-2 infectionPreprint

Bronder, S., Mihm, J., Urschel, R., Klemis, V., Schmidt, T., Marx, S., Abu‐Omar, A., Hielscher, F., Guckelmus, C., Widera, M., et al. (2023) · medRxiv · doi:10.1101/2023.08.13.23294045

Les coronavirus

Fleury, H. J. (2023) · Elsevier eBooks · doi:10.1016/b978-2-294-78221-3.00008-2

Enhanced Omicron subvariant cross-neutralization efficacy of a monovalent SARS-CoV-2 BA.4/5 mRNA vaccine encoding a noncleaved, nonfusogenic spike antigenPreprint

Seo, H. Y., Jung, H., Woo, H., Jung, H.-G., Cho, H., Bak, Y., Lee, S., Son, Y.-M., Yoon, G., Hwang, S.-Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.10.557088

Enhanced Omicron subvariant cross-neutralization efficacy of a SARS-CoV-2 BA.4/5 mRNA vaccine encoding a noncleaved, nonfusogenic spike antigenPreprint

Oh, J., Seo, H. Y., Jung, H., Woo, H., Jung, H.-G., Cho, H., Bak, Y., Lee, S., Son, Y.-M., Yoon, G., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3344007/v1

Broad protection from SARS-CoV-2 variants without antigen matching

Chappell, K. J. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00290-4

Repeated Omicron infection dampens immune imprinting from vaccination and induces broad neutralizing profiles against other Omicron sub-variantsPreprint

Yang, Y., Gong, X., Peng, L., Wang, F., Liu, J., Peng, Y., Niu, S., Yin, J., Guo, L., Tang, Y., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3320770/v1

Side effects of vaccines

Tom-Brophy, S., Konopnicki, A., Ambler, A. W., & Brooks, B. D. (2023) · Side effects of drugs annual · doi:10.1016/bs.seda.2023.09.010

The Omicron Strain of the SARS-CoV-2 Coronavirus and Its Variants

Sсherbak, S. G., Vologzhanin, D. A., Golota, A., Sarana, A., & Makarenko, S. (2023) · Journal of Clinical Practice · doi:10.17816/clinpract322036

Can a pan-coronavirus vaccine limit the threat of SARS-CoV-2 emerging variants and prevent any future pandemic?Preprint

Odhar, H. A. (2023) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/q4u5d

COVID-19 Antibody Testing in Healthcare Workers in Arkansas

Joshi, M., Theus, J. W., Joshi, A., Burns, M. C., & Bartter, T. C. (2023) · Cureus · doi:10.7759/cureus.48511

Insights into Viral Zoonotic Diseases: COVID-19 and Monkeypox

Sachdev, A. K., & Letchumanan, V. (2023) · Progress In Microbes & Molecular Biology · doi:10.36877/pmmb.a0000397 · Cited by 1

An omicron-specific neutralizing antibody test predicts neutralizing activity against XBB 1.5

Varvel, S. A., Galdzicka, M. M., Nystrom, S., Liu, H., Chen, G., Ragan, I. K., & Shabahang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1334250

Bivalent (Omicron BA.5/ancestral) recombinant spike protein vaccine: a promising booster

Zhang, R., & Hung, I. F. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00156-7

Incidence Rate of Covid-19 Infection in People with Fourth Dose of Vaccines Bivalent Mrna from October 2022 to October 2023 in A General Medicine Office in Toledo (Spain)

Turabián, J. L. (2024) · General medicine and Clinical Practice · doi:10.31579/2639-4162/133 · Cited by 1

Preclinical Evaluation of a Cross-Protective ß-SARS-CoV-2 Virus-Like Particle Vaccine Adjuvanted with MF59Preprint

Earnest, L., Fernandez‐Ruiz, D., Edeling, M. A., Montoya, J. C., Yap, A. H. Y., Wong, C. Y., Holz, L. E., Gras, S., Cooney, J. P., Davidson, K. C., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4771359

New approaches to vaccines for infectious diseases

Bagwe, P., Vijayanand, S., Patil, S., Akanksha, K., Menon, I., Gomes, K. B., Uddin, M. N., & D’Souza, M. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18564-9.00003-5

Public Health Response to SARS-CoV-2 in Assisted Living Facilities in New York State: March 2020-December 2022

D’Ascanio, A. M., Hewlett, D., Davda, K., & Montecalvo, M. A. (2024) · Journal of Public Health Management and Practice · doi:10.1097/phh.0000000000001878

COVID-19 antibody titers after tixagevimab–cilgavimab injection in patients with hematologic diseases; a single-center, prospective study

Nakamura, N., Tsunemine, H., Ikunari, R., Sakai, T., & Arima, N. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2343519

Suplemento da Sociedade Mineira de Pediatria

(2024) · Revista Médica de Minas Gerais · doi:10.5935/2238-3182.2024v34s101

Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults

Hu, H., Ma, F., Gong, L., Wang, Y., Xu, M., Sun, H., Hu, Q., Wang, P., Han, L., & Xie, H. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.058

Investigation of severe acute respiratory syndrome coronavirus 2 infection status in solid organ transplant recipients treated with tixagevimab/cilgavimab

Aihara, R., Umemura, K., Katada, Y., Nakagawa, S., Kobayashi, T., Hatano, E., Date, H., Nagao, M., & Terada, T. (2024) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2024.05.007

Approved vaccines for the COVID-19 pandemic: Linking in future perspectives

Fonseca, L. M. D. S., Hodel, K. V. S., Rocha, V. P. C., Soares, M. B. P., & Machado, B. A. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18703-2.00014-1

Older subjects and immunogenicity of mRNA COVID-19 vaccines

Seiffert, P., & Religa, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95648-2.00051-4

COVID-19 vaccines and their impact: An overview

Khong, K.-W., & Hung, I. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95646-8.00002-0

The Omicron variant of SARS-CoV-2

Zambrano, J. L., Jaspe, R. C., Loureiro, C. L., Rangel, H. R., Liprandi, F., & Pujol, F. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95646-8.00003-2

The Protective Efficacy of a SARS-CoV-2 Vaccine Candidate B.1.351V against Several Variant Challenges in K18-hACE2 Mice

Yang, J. E., Fan, H., Yang, A., Wang, W., Wan, X. H., Lin, F., Yang, D., Wu, J., Wang, K., Li, W., et al. (2024) · Vaccines · doi:10.3390/vaccines12070742

The Molecular and Biological Patterns Underlying Sustained SARS-CoV-2 Circulation in the Human Population

Kustova, D. D., Pochtovyi, A. A., Геннадьевна, Ш. О., Shtinova, I. A., Kuznetsova, N. A., Клейменов, Д. А., Komarov, A. G., & Gushchin, V. А. (2024) · Problems of Virology · doi:10.36233/0507-4088-242

Coronaviruses

Mostafa, H. H., & Pinsky, B. A. (2023) · ClinMicroNow · doi:10.1002/9781683674849.mcm0093

COVID-19 vaccines: A comprehensive review of safety and efficacy

Yan, Z., Yang, M., & Lai, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19170-1.00028-0

Coronaviruses

Mostafa, H. H., & Pinsky, B. A. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0093

Non-Inferiority Phase 2 Immunogenicity and Safety Study of 'Comvigen': A Model for Mrna Vaccine Development in Low- and Middle-Income Countries (LMICs)Preprint

Jantarabenjakul, W., Nantanee, R., Puthanakit, T., Gatechompol, S., Avihingsanon, A., Punrin, S., Tantawichien, T., Nitayaphan, S., Thitithanyanont, A., Buranapraditkun, S., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5158553

Immune Imprinting, Non-Durable Hybrid Immunity, and Hybrid Immune Damping Following SARS-CoV-2 Primary Vaccination with BNT162b2 and Boosting with mRNA-1273

Erice, A., Nuño, N., Prieto, L., & Caballero, C. (2025) · Vaccines · doi:10.3390/vaccines13030310

A meta-analysis on the immunogenicity of prototype, monovalent-adapted and bivalent vaccines against SARS-CoV-2 wildtype, Omicron BA.1 and Omicron BA.4/5 in healthy adults

Ndzouboukou, J. B., Kamara, A. A., Ullah, N., Lei, Q., & Fan, X. (2025) · Virology · doi:10.1016/j.virol.2025.110509

2′-O-methylation and N6-methyladenosine enhance the oral delivery of small RNAs in mice

Guo, S., Li, Z., Li, X., Liang, Z., Zhao, D., Sun, N., Liu, J., Wang, X., Mei, S., Qiao, X., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102574

Evaluation of Simultaneous Production Strategies for Adenoviral Vector-Based SARS-CoV-2 Multivalent Vaccines via an Expanded Allele-specific Competitive Blocker PCR Quantification Method

Chang, S., Park, H. M., Shin, J., Park, S., Park, B., & Kang, C. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c01281

Neutralizing antibody response to Omicron subvariants BA.1 and BA.5 in children and adolescents following the two-dose CoronaVac protocol (Immunita-002, Brazil): a 12-month longitudinal study

Corsini, C. A., Campos, G. R. F., Martins, P. F. D. S., Filgueiras, P. S., Lima, A. E. D. S., Gomes, S. V. C., Curimbaba, C., Lorencini, D. A., Morandi, E., da Silva, V. M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1589733

Immune responses to a heterologous booster with mRNA based COVID-19 vaccine after priming with an inactivated Newcastle disease virus recombinant vaccine expressing the SARS-CoV-2 spike protein (NDV-HXP-S)

Luvira, V., Lawpoolsri, S., Phumratanaprapin, W., Jongkaewwattana, A., Nanthapisal, S., Muangnoicharoen, S., Kamolratanakul, S., Sabmee, Y., Duangdee, C., Narakorn, P., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127601

Neutralizing activity against Omicron subvariants BA.1, BA.2, and BA.4/5 following the third SARS-CoV-2 vaccination in cancer patients undergoing chemotherapy

Yun, J., Kim, B., Kim, H., Lim, S. H., Choi, S. H., Kim, J. Y., Kim, H. J., & Park, S. K. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100757

COVID-19, RSV and the flu are straining health care systems – two epidemiologists explain what the ‘triple threat’ means for children

Fischer, R. S. B., & Regan, A. K. (2022) · doi:10.64628/aai.hxt9vnekt

Bivalent mRNA vaccine booster enhances immunity against XBB.1.5 more effectively than breakthrough infection in K18-hACE2 mice

Linger, M. E., Jorritsma, S. H. T., Horst, J. B.-T., Zevenhoven-Dobbe, J. C., Rijlaarsdam, F., Colstrup, E., Beijnes, M., de Vries, J. J. C., Arens, R., Murugan, R., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113479 · Cited by 1

LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19

Chalkias, S., Harper, C., Vrbicky, K. W., Walsh, S. R., Essink, B. J., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac492.1873

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Preprint

Chalkias, S., Whatley, J. L., Eder, F. S., Essink, B. J., Khetan, S. K., Bradley, P., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., et al. (2022) · medRxiv · doi:10.1101/2022.12.11.22283166 · Cited by 9

A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273Preprint

Lee, I. T., Cosgrove, C. A., MOORE, P. J., Bethune, C., Nally, R., Bula, M., Kalra, P. A., Clark, R., Dargan, P. I., Boffito, M., et al. (2023) · medRxiv · doi:10.1101/2023.01.24.23284869 · Cited by 9

2363. Three-Month Safety and Immunogenicity of Bivalent SARS-CoV-2 Omicron-Containing Booster Vaccines: Interim Results From a Phase 3, Randomized, Observer-Blind, Active-Controlled Trial

Lee, I. T., Cosgrove, C. A., MOORE, P. J., Bula, M., Kalra, P. A., Dargan, P. I., Clark, R., Boffito, M., Sheridan, R., Bethune, C., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad500.1984 · Cited by 1

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

Chalkias, S., Whatley, J. L., Eder, F. S., Essink, B. J., Khetan, S. K., Bradley, P., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02517-y · Cited by 72